Zhongguo shi yan xue ye xue za zhi · 2024
[Expression and Clinical Significance of miR-383-5p in Multiple Myeloma Cells].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Lin, Yang Yan-Li, Zhang Feng, Li Jia-Jia
Аннотация
OBJECTIVE: To investigate the expression of miR-383-5p in newly diagnosed multiple myeloma (MM) and its correlation with clinical features and prognosis.
METHODS: 115 MM patients diagnosed and treated in the Department of Hematology, the First Affiliated Hospital of Bengbu Medical University from January 2013 to January 2017 and 115 non-tumor controls were enrolled in this study. Clinical characteristics, pathological data and therapeutic responses of the patients were collected. The expression of miR-383-5p in MM patients and non-tumor controls was detected by RT-qPCR, and the relationship between the expression level of miR-383-5p and the clinical characteristics and prognosis of MM patients was further analyzed.
RESULTS: The results of RT-qPCR showed that the relative expression levels of miR-383-5p in bone marrow tissues of 115 non-tumor controls and 115 MM patients were 1.89±0.11 and 1.48±0.13, respectively, and the difference was statistically significant (P < 0.05). Chi-square analysis showed that the expression of miR-383-5p was correlated with bone injury, β2-microglobulin and globulin (all P < 0.001), but not with other factors including age, sex, hemoglobin and light chain. Univariate and multivariate Cox regression analysis indicated that low expression of miR-383-5p was an independent risk factor for poor OS in MM patients (P < 0.001).
CONCLUSION: The expression of miR-383-5p is down-regulated in MM patients, and low expression of miR-383-5p is a risk factor for poor prognosis and can be used as a new prognostic biomarker.
METHODS: 115 MM patients diagnosed and treated in the Department of Hematology, the First Affiliated Hospital of Bengbu Medical University from January 2013 to January 2017 and 115 non-tumor controls were enrolled in this study. Clinical characteristics, pathological data and therapeutic responses of the patients were collected. The expression of miR-383-5p in MM patients and non-tumor controls was detected by RT-qPCR, and the relationship between the expression level of miR-383-5p and the clinical characteristics and prognosis of MM patients was further analyzed.
RESULTS: The results of RT-qPCR showed that the relative expression levels of miR-383-5p in bone marrow tissues of 115 non-tumor controls and 115 MM patients were 1.89±0.11 and 1.48±0.13, respectively, and the difference was statistically significant (P < 0.05). Chi-square analysis showed that the expression of miR-383-5p was correlated with bone injury, β2-microglobulin and globulin (all P < 0.001), but not with other factors including age, sex, hemoglobin and light chain. Univariate and multivariate Cox regression analysis indicated that low expression of miR-383-5p was an independent risk factor for poor OS in MM patients (P < 0.001).
CONCLUSION: The expression of miR-383-5p is down-regulated in MM patients, and low expression of miR-383-5p is a risk factor for poor prognosis and can be used as a new prognostic biomarker.